Frontotemporal Dementia Clinic Launches Phase 3 Trial - Vanderbilt Discover
Vanderbilt University Medical Center Discover,
April 20, 2022 People with genetic progranulin insufficiency are targeted for early disease-course disruption.
First Round of FTD Therapeutics Fell Short, But Many More Are Up and Running
Alzforum,
27 Sep 2016 Even as researchers work to unearth the underlying causes of frontotemporal dementia, they are beginning to develop…